(untitled)
Inês Pires da Silva(The University of Sydney), Alexander M. Menzies(The University of Sydney), Lauren E. Haydu(The University of Texas MD Anderson Cancer Center), Ana Arance(Hospital Clínic de Barcelona), Jessica L. Smith(Blacktown & Mount Druitt Hospital), H.K. Oberoi(Hospital Clínic de Barcelona), Patricio Serra-Bellver(The Christie Hospital), Rudolf Herbst(Helios Klinikum Erfurt), Ralf Gutzmer(University Hospitals of the Ruhr-University of Bochum), Michael Weichenthal(Christian-Albrechts-Universität zu Kiel), Claudia Pföhler(Saarland University), Douglas B. Johnson(Vanderbilt University Medical Center), Lisa Pickering(Royal Marsden Hospital), Judith M. Versluis(The Netherlands Cancer Institute), Dirk Schadendorf(National Center for Tumor Diseases), John Park(California Baptist University), Tasnia Ahmed(The University of Sydney), Caroline A. Nebhan(VA Tennessee Valley Healthcare System), Serigne Lo(The University of Sydney), Peter Mohr(Elbe Kliniken Stade-Buxtehude), Michael A. Davies(The University of Texas MD Anderson Cancer Center), Tim Slattery(Royal Marsden NHS Foundation Trust), Selma Ugurel(Klinikum Bielefeld), Paul Lorigan(Manchester Academic Health Science Centre), Georgina V. Long(The University of Sydney), James Larkin(Trinity College Dublin), Jennifer L. McQuade(The University of Texas MD Anderson Cancer Center), Matteo S. Carlino(The University of Sydney), Richard A. Scolyer(The University of Sydney), Yasir Khan(St John of God Hospital), Christian U. Blank(The Netherlands Cancer Institute), Patrick Terheyden(University Hospital Schleswig-Holstein), Rajat Rai(The University of Sydney), Jochen Utikal(German Cancer Research Center)
Research Explorer (The University of Manchester)
January 1, 2000
Cited by 77
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.9k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2019|3.7k